BSECompany Update4d ago · 30 Jul 2026, 09:08 pm

Please find the enclosed document of the Company in relation to the captioned subject for your reference.

AstraZeneca Pharma India Ltd · 506820

✦ AI Summary▼ NegativeRegulatory

AstraZeneca Pharma India Ltd has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013, amounting to Rs. 148.65 crore, including interest.

Analysis Scores

Earnings Impact2/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment2/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

AstraZeneca Pharma India Ltd - 506820 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Attachments (1)

📄

5fa5acba-060a-4991-afce-8880dc0b5bab.pdf

pdf

Download →
View document text
July 30, 2026 The Manager- Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai – 400 001 The Manager- Listing National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex, Bandra (E), Mumbai – 400 051 Dear Sir/Madam, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our communication dated September 12, 2025, we hereby inform that the Company has received a demand notice issued by the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The Company is currently evaluating the demand notice and appropriate legal actions. In this regard, please find the details as required under the SEBI Circular HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026 attached herewith as Annexure – A. Kindly take the above information on record. Thanking You, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer Annexure – A Sl. No. Particulars Details 1. Name of the authority National Pharmaceutical Pricing Authority (NPPA) 2. Nature and details of the Demand Notice issued by the NPPA for action(s) alleged overcharging under the Drugs (Prices Control) Order, 2013 (‘DPCO, 2013’) of Rs. 1,48,65,83,590/- inclusive of interest calculated upto August 20, 2026. 3. Date of receipt of direction or July 29, 2026 order, including any ad-interim or interim orders, or any other communication from the authority 4. Details of the Further to a show cause notice violation(s)/contravention(s) dated September 11, 2025, the Company has committed or alleged to be received a demand notice from NPPA on July committed 29, 2026, in relation to Symbicort Turbuhaler 160/4.5 (Inhaler). NPPA has alleged overcharging for the period from May 2016 to November 2025 under DPCO, 2013 and has demanded Rs. 1,48,65,83,590/-, including interest, payable within 30 days from receipt of the notice. The Company is currently evaluating the demand notice and appropriate legal actions. 5. Impact on financial, operation or Rs. 1,48,65,83,590/- inclusive of interest other activities of the listed calculated upto August 20, 2026. entity, quantifiable in monetary terms to the extent possible